TLDRJohnson & Johnson delivered Q2 adjusted EPS of $2.90, surpassing analyst expectations of $2.85Second-quarter revenue reached $25.31 billion, representing 6.6% year-over-year growth and exceeding forecastsCompany increased full-year revenue outlook to approximately $101.1 billion; adjusted EPS guidance now stands at $11.68 midpointTremfya revenue jumped 72.5% to reach $2 billion; Darzalex generated $4.2 billion in quarterly salesShares declined approximately 2% in premarket hours despite positive earnings and upgraded guidanceJohnson & Johnson delivered second-quarter results that exceeded analyst projections, yet the stock fell despite the positive news. Shares of JNJ dropped approximately 2% during premarket hours on Wednesday, even after management upgraded its full-year financial targets.Johnson & Johnson, JNJThe healthcare giant posted adjusted earnings per share of $2.90, surpassing the Street’s consensus estimate of $2.85. Revenue totaled $25.31 billion for the quarter, marking a 6.6% increase compared to the prior-year period and exceeding analyst projections of $25.05 billion.The negative market response made sense in context. Shares of J&J had already climbed nearly 23% year-to-date through 2026 before the earnings release, substantially outperforming the S&P 500’s 10% advance. With that kind of run-up, results that merely met elevated expectations weren’t sufficient to drive further gains.$JNJ Q2’26 EARNINGS HIGHLIGHTS Sales: $25.31B (Est. $25.02B) ; +6.6% YoY Adj EPS: $2.90 (Est. $2.86) ; +4.7% YoY Adj Net Earnings: $7.08B; +5.7% YoYFY26 Guide: Sales: $100.8B to $101.4B (Est. $101.06B) ; +7.3% YoY Adj EPS: $11.60 to $11.75 (Est. $11.58)…— Wall St Engine (@wallstengine) July 15, 2026The pharmaceutical business emerged as the quarter’s strongest performer. The division generated $16.38 billion in sales, exceeding analyst expectations of $16.1 billion.Tremfya delivered particularly impressive results. The treatment for psoriasis and inflammatory bowel disease recorded $2 billion in quarterly revenue, representing a 72.5% surge versus the same quarter last year and significantly above LSEG projections of $1.74 billion. Tremfya has become increasingly critical for J&J’s growth strategy as the company works to offset revenue losses from Stelara, which has experienced steep declines following the introduction of biosimilar alternatives in 2025.Darzalex, used to treat blood cancers, brought in $4.2 billion during the quarter, aligning closely with Wall Street predictions. Meanwhile, Carvykti and Tecvayli helped propel 6.8% expansion in the Innovative Medicine oncology portfolio.MedTech Drags, Impella in FocusThe MedTech segment represented the quarter’s underperformer. Revenue totaled $8.93 billion, achieving 4.5% growth but missing the $9 billion threshold analysts had anticipated.A notable concern within MedTech involved Impella heart pump sales, which declined 2% year-over-year. This marked a significant shift from the 14% expansion recorded during the first quarter. CFO Joseph Wolk pointed to a United Kingdom research study released earlier this year that questioned the device’s effectiveness in certain high-risk coronary interventions.Wolk stated that J&J anticipates the product line will resume growth as additional supporting evidence becomes available. “We have a big data set coming out probably in the first half of next year that should allay any fears,” he explained.Guidance RaisedManagement increased its full-year projections across both revenue and earnings metrics. The company now forecasts sales of roughly $101.1 billion at the midpoint, an increase from the prior estimate of $100.8 billion. Adjusted EPS guidance was elevated to $11.68 at the midpoint, compared to the previous target of $11.55.Wells Fargo analyst Lawrence Biegelsen had observed prior to the earnings announcement that J&J had raised its sales outlook during a second-quarter report only once over the past four years, suggesting the move could signal positive momentum.J.P. Morgan analyst Chris Schott characterized J&J as “one of the cleaner names” within its sector as the company transitions beyond the Stelara patent expiration challenges.According to Wolk, J&J now operates 28 distinct platforms that each produce at least $1 billion in annual sales.The post Why Johnson & Johnson (JNJ) Stock Declined Despite Strong Q2 Earnings Beat appeared first on Blockonomi.